Home

Roivant Sciences Ltd. - Common Shares (ROIV)

15.09
-0.19 (-1.24%)
NASDAQ · Last Trade: Sep 18th, 7:06 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
6 Analysts Assess Roivant Sciences: What You Need To Knowbenzinga.com
Via Benzinga · September 18, 2025
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17stocktwits.com
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said.
Via Stocktwits · September 17, 2025
Why Roivant Sciences Stock Is Soaring Todayfool.com
The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug.
Via The Motley Fool · September 17, 2025
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trialbenzinga.com
Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.
Via Benzinga · September 17, 2025
Wednesday's session: gap up and gap down stockschartmill.com
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · September 17, 2025
A Glimpse of Roivant Sciences's Earnings Potentialbenzinga.com
Via Benzinga · August 8, 2025
What Does the Market Think About Roivant Sciences?benzinga.com
Via Benzinga · July 23, 2025
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · September 17, 2025
Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Diseaseinvestors.com
The company is working on a treatment for an autoimmune disease that affects the skin and muscles.
Via Investor's Business Daily · September 17, 2025
Why Roivant Sciences Stock Bounced Back on Tuesdayfool.com
Investors were in a forgiving mood after Monday's dispiriting earnings release.
Via The Motley Fool · August 12, 2025
Why Roivant Sciences Stock Was Slipping on Mondayfool.com
The distinctive biotech wasn't a sector favorite as the trading week began.
Via The Motley Fool · August 11, 2025
Peering Into Roivant Sciences's Recent Short Interestbenzinga.com
Via Benzinga · June 25, 2025
Roivant Sciences's Earnings Outlookbenzinga.com
Via Benzinga · May 28, 2025
Roivant Sciences Q3 Earnings Assessmentbenzinga.com
Via Benzinga · February 10, 2025
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings. These reports, ranging from cybersecurity and fintech to mining and life sciences, offer a crucial granular view into
Via MarketMinute · August 11, 2025
Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday?benzinga.com
Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion of President Donald Trump’s tari
Via Benzinga · May 29, 2025
Earnings Scheduled For August 11, 2025benzinga.com
Via Benzinga · August 11, 2025
Earnings Scheduled For May 29, 2025benzinga.com
Via Benzinga · May 29, 2025
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shiftinvestors.com
The company is getting a new chief executive and a new chief financial officer amid sweeping changes.
Via Investor's Business Daily · April 21, 2025
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Databenzinga.com
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.
Via Benzinga · March 19, 2025
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.investors.com
The companies reported positive results for their lead asset in patients with two rare diseases.
Via Investor's Business Daily · March 19, 2025
Roivant Sciences Tops Q3 Expectationsfool.com
Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.
Via The Motley Fool · February 10, 2025
Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?benzinga.com
Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while awaiting further clarity on trade policie
Via Benzinga · February 10, 2025
Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching
President Trump's cabinet is comprised of millionaires, billionaires and leaders in business who founded or led public companies. Here's the TRUMP index stocks.
Via MarketBeat · January 28, 2025
Earnings Scheduled For February 10, 2025benzinga.com
Via Benzinga · February 10, 2025